Form 8-K Cannabics Pharmaceutical For: Jan 29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 29th, 2018
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Nevada | 000-52403 | 20-3373669 |
(State of incorporation) | (Commission File Number) | (IRS Employer No.) |
#3 Bethesda Metro Center
Suite 700
Bethesda, Md 20814
(Address of principal executive offices and Zip Code)
877-424-2429
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On January 29th, 2018, Itamar Borochov stepped down as Director and CEO of the Company. His resignation was not the result of any dispute with the Corporation. On the same date, the shareholders of the Corporation elected Ehud Rieger to the position of Director and Board Member. Additionally, the shareholders elected current Director and COO Eyal Barad to the position of CEO.
Eyal Barad 52, is a co-founder of Cannabics Inc., founded in 2012, and is a core member of Cannabics Inc.’s management team and brings 20 years of executive managerial experience in successful technology and startup ventures. Mr. Barad received his BA in Economics & International Relations from the Hebrew University in Jerusalem in 1994, and an MBA with Honors from Haifa University in 2007.
Ehud Rieger, 56, brings 30 years of executive corporate experience, is Manager of Alrig Investments & Finance Ltd. since 1991, and is a Board Member of several private and public companies. He held the rank of Major in the Israeli Defense Forces. Ehud obtained his Law Degree from Tel Aviv University in 1989, and MBA at INSEAD in Fontainebleau, France, in 1990.
Related Party – Both Barad and Rieger are shareholders of Cannabics Inc., a Delaware corporation and majority shareholder of the Company.
ITEM 9.01 FINANCIAL STATEMENTS & EXHIBITS
(d) Exhibits
Exhibit No. | Description |
10.1 | Shareholder’s Resolution |
10.2 | Resolution of the Board of Directors regarding resignation of Itamar Borochov |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 30, 2018
Cannabics Pharmaceuticals Inc. | |
By: /s/ Eyal Barad | |
Eyal Barad, Director, CEO |
Exhibit 10.1
RESOLUTION OF THE SHAREHOLDERS
OF
CANNABICS PHARMACEUTICALS INC.
The following is a true copy of the resolution duly adopted by the Majority (74%) of the Shareholders of the Corporation at a special meeting, notice to this meeting having been waived, held this 29th day of January, 2018;
WHEREAS there has been presented to and considered by this meeting a Motion to Accept the Resignation of Itamar Borochov as Director and CEO; to Vote that Eyal Barad assume the position as CEO, and to vote Ehud Rieger as a new Director and Board Member.
NOW THEREFORE BE IT RESOLVED that the majority of shareholders having considered this matter, and having opened the floor to all those who voice a preference in the issue and pursuant to NRS 78.320, have overwhelmingly decided and RESOLVED that:
The Corporation hereby ACCEPTS the Resignation of Itamar Borochov;
That it VOTED Ehud Rieger as a Director and Board Member;
That it VOTED for Eyal Barad to assume the position of CEO.
The Above qualified people have been nominated, and have accepted their position as DIRECTORS and OFFICERS of the Company.
Said Motion is hereby passed and the corporate books, records and the Company shall file this Resolution in the corporate records.
Dated: 29th January, 2018
/s/ Eyal Barad
Eyal Barad,
on behalf of Cannabics, Inc., Majority Shareholders
Exhibit 10.2
RESIGNATION FROM
THE BOARD OF DIRECTORS
OF
CANNABICS PHARMACEUTICALS INC.
The following is a true copy of the resolution duly adopted by the Board of Directors of the Corporation at a special meeting, notice to this meeting having been waived, held on 29th January, 2018.
The Board of Directors who were present for this meeting & took active part therein were:
DR. EYAL BALLAN
ITAMAR BOROCHOV
EYAL BARAD
WHEREAS there has been presented to and considered by this meeting a Motion that I, ITAMAR BOROCHOV formally RESIGN and renounce all further corporate designation or affiliation with Cannabics Pharmaceuticals Inc., Cannabics, Inc., and Grin Ultra Ltd.
NOW THEREFORE BE IT RESOLVED that the corporation having considered this matter, has opened the floor to all those who voice a preference in the issue, has decided unanimously and RESOLVED that: I do hereby formally RESIGN, and sever any and all official ties, duties, obligations or liabilities regarding Cannabics Pharmaceuticals Inc. and, by affixing, my signature hereto, officially as my last corporate act, DO HEREBY RESIGN.
The Director and CEO of the corporation, by affixing his signature hereto, does hereby formally resign.
DATED: 29th January, 2018
/s/ Itamar Borochov
Itamar Borochov
Cannabics Pharmaceuticals Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dune Real Estate Partners Announces Promotions
- International Harrington Prize Awarded to Dr. Arlene Sharpe
- Kvika banki hf.: Hugrún Sif Harðardóttir appointed internal auditor of Kvika banki hf.
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!